EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor

被引:14
作者
Koo, J. S. [1 ]
Kim, S. H. [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, Seoul, South Korea
关键词
brain metastasis; EGFR; lung neoplasm; HER-2; immunohistochemistry; GROWTH-FACTOR-RECEPTOR; GENE COPY NUMBER; HER2/NEU EXPRESSION; PROTEIN EXPRESSION; GEFITINIB; ADENOCARCINOMA; AMPLIFICATION; SENSITIVITY; SURVIVAL; THERAPY;
D O I
10.4149/neo_2011_01_27
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated EGFR and HER-2 status in brain metastatic non-small cell lung cancer (NSCLC) and compared them to EGFR and HER-2 status of primary NSCLC. Evaluated were 66 cases of brain metastatic NSCLC, including 20 cases of corresponding primary NSCLC. HER-2 status was investigated by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), and EGFR status was evaluated by IHC. HER-2 overexpression and/or amplification was/were observed in three cases (4.5 %) of 66 cases of brain metastatic NSCLC, and 23 cases (34.8%) demonstrated EGFR overexpression. Among 20 cases of primary and corresponding metastatic NSCLC, one case showed HER-2 overexpression and amplification in both primary and metastatic tumor. On the other hand, EGFR overexpression was noted in four cases of primary NSCLC and nine cases of metastatic NSCLC. Five cases showed EGFR gain in metastatic NSCLC. Brain metastatic NSCLC demonstrated different expression patterns of the abovementioned biomarkers, particularly EGFR when compared to primary NSCLC. Therefore, HER-2 and EGFR status are suggested to be evaluated in brain metastatic NSCLC for targeted monotherapy.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [41] EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
    Xu, Jian Ming
    Han, Yu
    Duan, Hai Qing
    Gao, E. Mei
    Zhang, Yang
    Liu, Xiao Qing
    Zhang, Jing Sheng
    Toschi, Luca
    Galetta, Domenico
    Azzariti, Amalia
    Paradiso, Angelo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 771 - 782
  • [42] Leptomeningeal metastasis in patients with non-small cell lung cancer after stereotactic radiosurgery for brain metastasis
    Chiang, Chi-Lu
    Yang, Huai-Che
    Luo, Yung-Hung
    Chen, Ching-Jen
    Wu, Hsiu-Mei
    Chen, Yuh-Min
    Hu, Yong-Sin
    Lin, Chung-Jung
    Chung, Wen-Yuh
    Shiau, Cheng-Ying
    Guo, Wan-Yuo
    Chou, Teh-Ying
    Pan, David Hung-Chi
    Lee, Cheng-Chia
    JOURNAL OF NEUROSURGERY, 2023, 139 (02) : 385 - 392
  • [43] Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer
    Aviles-Salas, Alejandro
    Muniz-Hernandez, Sae
    Maldonado-Martinez, Hector Aquiles
    Chanona-Vilchis, Jose G.
    Ramirez-Tirado, Laura-Alejandra
    Hernandez-Pedro, Norma
    Dorantes-Heredia, Rita
    Ruiz-Morales, Jose Manuel
    Motola-Kuba, Daniel
    Arrieta, Oscar
    ONCOLOGY LETTERS, 2017, 13 (02) : 912 - 920
  • [44] Association between smoking status and the prognosis of brain metastasis in patients with non-small cell lung cancer
    Zhang, Xiaofang
    Zeng, Weilin
    Yan, Xingyu
    Wang, Zheng
    Xu, Ke
    Li, Mo
    Wang, Tianlu
    Song, Yingqiu
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    Eichler, April F.
    Kahle, Kristopher T.
    Wang, Daphne L.
    Joshi, Victoria A.
    Willers, Henning
    Engelman, Jeffrey A.
    Lynch, Thomas J.
    Sequist, Lecia V.
    NEURO-ONCOLOGY, 2010, 12 (11) : 1193 - 1199
  • [46] Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer
    Li, Lina
    Luo, Shuimei
    Lin, Heng
    Yang, Haitao
    Chen, Huijuan
    Liao, Ziyuan
    Lin, Wanzun
    Zheng, Weili
    Xie, Xianhe
    JOURNAL OF THORACIC DISEASE, 2017, 9 (08) : 2510 - 2520
  • [47] HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
    Suzuki, Mikiko
    Shiraishi, Kouya
    Yoshida, Akihiko
    Shirnada, Yoko
    Suzuki, Kenji
    Asamura, Hisao
    Furuta, Koh
    Kohno, Takashi
    Tsuta, Koji
    LUNG CANCER, 2015, 87 (01) : 14 - 22
  • [48] Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer
    Shimizu, Katsuhiko
    Yukawa, Takuro
    Hirami, Yuji
    Okita, Riki
    Saisho, Shinsuke
    Maeda, Ai
    Yasuda, Koichiro
    Nakata, Masao
    TARGETED ONCOLOGY, 2013, 8 (04) : 237 - 242
  • [49] MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis
    Qi, H.
    Hou, Y.
    Zheng, Z.
    Zheng, M.
    Sun, X.
    Xing, L.
    CLINICAL RADIOLOGY, 2024, 79 (07) : 515 - 525
  • [50] Impact of EGFR mutation analysis in non-small cell lung cancer
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    Mitsudomi, Tetsuya
    LUNG CANCER, 2009, 63 (03) : 315 - 321